{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:35:40Z","timestamp":1763757340428,"version":"3.45.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bulcan.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:50:54Z","timestamp":1761220254000},"page":"1358-1359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blinatumomab dans la leuc\u00e9mie aigu\u00eb lymphoblastique B sans chromosome de Philadelphie en r\u00e9mission compl\u00e8te avec persistance d\u2019une maladie r\u00e9siduelle positive"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-8687","authenticated-orcid":false,"given":"Mathilde","family":"Chanut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.09.003_bib0030","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2025.09.003_bib0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bulcan.2022.01.003","article-title":"[Blinatumomab as monotherapy in consolidation treatment after first relapse of Ph-CD19+ ALL in children over one year old]","volume":"109","author":"Coppin","year":"2022","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.09.003_bib0040","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024\u00a0ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.09.003_bib0045","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bulcan.2022.09.006","article-title":"[New European approval: Brexucabtagene autoleucel in adult relapsed\/refractory acute lymphoblastic leukemia]","volume":"109","author":"Lemoine","year":"2022","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.09.003_bib0025","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125004485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125004485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:31:08Z","timestamp":1763757068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125004485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":5,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0007455125004485"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.09.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blinatumomab dans la leuc\u00e9mie aigu\u00eb lymphoblastique B sans chromosome de Philadelphie en r\u00e9mission compl\u00e8te avec persistance d\u2019une maladie r\u00e9siduelle positive","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}